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ABSTRACT
The sensitive version of cell-ELISA was developed for the subtype-specific differentiation of current influenza A(H1N1)pdm09 
and A(H3N2) viruses that are circulating in the human population. This method is based on the estimation of virus reproduction 
in infected MDCK cells. The detection step of this method is an interaction of the subtype-specific monoclonal antibodies (mAbs) 
with the viral hemagglutinin (НА) molecule. The influenza A virus strains, isolated in the 2014 epidemic season, were used to 
validate this method.
It was shown that when using mAbs # 1/ # 2 or # 4 at a concentration of 10-15 µg/ml, the developed variant of cell-ELISA was 
able to detect НА protein synthesized in the infected cells of influenza A(H3N2) and A(H1N1)pdm09 viruses, respectively.
The developed method can be used for the identification of modern influenza A viruses with low hemagglutination activity, 
which is not possible by the conventional hemagglutination inhibition test.
INTRODUCTION
Influenza is one of the most widespread infectious 
diseases. Around 50 million infectious disease cases 
are recorded annually in Russia. Severe acute respiratory 
illnesses (SARI), including influenza comprise 95% of 
all recorded cases. The influenza morbidity among the 
children is 7 to 10 times higher than that among the adult 
population. According to the data of the Federal Influenza 
and SARI Centers, the number of morbidity and mortality 
cases increases significantly during the influenza 
pandemic compared to the annual epidemics [1]. 
The high probability of the emergence of new 
pathogens, including the potential pandemic variants 
of the influenza viruses, is recognized by the World 
Health Organization (WHO) as an important reason for 
the continuous improvement of the respiratory virus 
surveillance service. This is particularly important in 
order to recognize forthcoming pandemics and to identify 
new influenza viruses as early as possible [2].
Since the SARI of a different etiology often have very 
close clinical symptoms, especially in the beginning 
of the disease, having a proper diagnostic becomes 
especially important. The early identification of the 
influenza infection makes it possible to prescribe 
the corresponding treatment to the patient at the 
very beginning of the illness in order to prevent the 
development of other secondary infections and limit 
the use of antibiotics. The timely determination of the 
nature of epidemic outbreaks is necessary to determine 
the tactics for conducting the anti-epidemic campaign 
and to plan the urgent preventive measures. In this 
connection, the optimization and development of the 
effective diagnostics of influenza and other SARI is an 
important issue.
The most common method of identification of the 
newly isolated influenza viruses is the hemagglutination 
inhibition assay (HAI) with the use of specific immune 
animal sera. This method allows for the determination 
of the specificity of the antigen – antibody interaction. 
However, the continuous accumulation of the evolutional 
mutations in the hemagglutinin (HA) molecule of 
influenza A(H1N1) and especially A(H3N2) strains during 
the last decade have brought changes to the HA receptor-
binding site that in turn led to the reduction of HA affinity 
to the receptors of different types of erythrocytes [3-6]. 
This effect complicates the identification of the subtype 
of some modern virus strains by HAI test.
One of the alternative methods of the identification 
of modern influenza viruses is micro cell-ELISA. 
This method is based on the estimation of the virus 
reproduction in infected cells by using high specific 
monoclonal antibodies (mAbs) that interact with the 
virus proteins. Cell-ELISA with the use of specific mAb 
to the virus NP protein was recommended by the WHO 
for the measurement of virus neutralizing antibodies 
in a microneutralization assay [7]. This method is also 
successfully used for the detection of the virus strains 
that react poorly in HAI [8]. 
Since the structure of NP protein is highly conserved 
for influenza viruses of different subtypes, cell-ELISA 
with mAb specific to the NP protein allows for the 
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detection of all subtypes of the influenza virus A strains, 
but it does not allow for differentiating the virus subtype. 
The goal of this project was to develop a sensitive 
version of the cell-ELISA that is suitable for the 
identification of the subtype of modern influenza 
A(H1N1)pdm09 and A(H3N2) strains with the use of a 
subtype specific mAbs to the viral HA. 
MATERIALS AND METHODS
Isolation of the influenza viruses from the clinical 
samples
The influenza virus A strains used in this study were 
isolated from the clinical samples of the patients infected 
by influenza and SARI from different cities of the Russian 
Federation in the 2014 epidemic season. 
The isolation of influenza viruses from the clinical 
samples was performed in the Madin Darby canine 
kidney (MDCK) cell line or in chicken embryos according 
to the Laboratory recommendations for virus isolation 
[9]. The identification of the isolated influenza strains 
was performed by means of HAI and polymerase chain 
reaction (PCR). 
The hemagglutination and hemagglutination 
inhibition assays
The hemagglutination and HAI assays were performed 
by using the standard method according to the Practical 
recommendations [10]. The human erythrocytes (Rh+ 
group 0) were used in order to enhance the method 
sensitivity.
PCR
PCR was accomplished using the reagent set “AmpliSence” 
(“InterLabService”, Moscow) according to the 
manufacturer’s instructions. Isolation of the RNA from the 
samples was carried out using the “AmpliSenseRIBoprep” 
and reverse transcription of the virus RNA using the 
“AmpliSenseReverta” kits. The systems “AmpliSense® 
Influenzavirus A/B-FL” (analysis of RNA of the influenza 
A and B virus strains), “AmpliSense® Influenzavirus A 
type FL” (identification of the subtypes of influenza viruses 
H1/H3) and “AmpliSense® Influenzavirus A/H1-swine-FL” 
(detection of the influenza virus A(H1N1)pdm09) were 
used to perform the real-time PCR.
Preparation of the mAbs
The mAbs for the influenza A(H3N2) and A(H1N1)pdm09 
viruses were prepared according to the described method 
[11] with some modifications. Balb/c mice or F1 hybrids 
(Balb/c x SJL/J) were immunized intraperitoneally (ip) 
by influenza virus purified by ultracentrifugation in the 
sucrose gradient. In several weeks, animals were boosted 
by the purified HA of the same virus. In 3 days post last 
immunization, the splenocytes of immunized mice were 
hybridized with the cells of the mouse myeloma cell 
line X63Ag8.653 in the presence of 50% PEG-2000. The 
cloning of hybrid cells was performed by the limiting 
dilution assay. First, the screening of the clones was done 
by classical ELISA in virus-coated plates with subsequent 
detection of mAbs by second mouse antibodies bound 
to horseradish peroxidase (Sigma, USA). Subsequently, 
cloning of the hybrid clones was done with the use of 
selective HAT medium. Finally, stable clones were used 
for the preparation of ascites.  For this purpose, Balb/c 
or F1 hybrid (Balb/c x SJL/J) mice primed by Pristane 
(0.5 ml per animal) were immunized intraperitoneally by 
hybrid cells (3-5x106 cells per animal). The ascites were 
collected 2-3 weeks post immunization. All of the work 
with animals was done in accordance with the “Specific 
regulations for the use of experimental animals” of the 
Russian Ministry of Health from 6/19/2003, number 266.
Micro cell-ELISA for influenza A and B viruses
Virus reproduction in the cells was estimated by the 
detection of the viral HA in an infected cell. For this 
purpose, 100 µl of the virus containing liquid was added 
to the 96-well plates (Nunc, Denmark) with a monolayer 
of MDCK cells. The plates were incubated at 37°C and 5% 
CO2. The medium used for virus cultivation was alpha-
MEM (“Biolot”, Russia) supplemented with 0.2% of 
bovine serum albumin (fraction V) (Sigma, USA), 0.05% 
arginine (Sigma, USA), and 2  µg/ml of TPCK-treated 
trypsin (Sigma, USA). 
After 48-96 h of incubation, whether the cytopathic 
effect was visible or not, the cell supernatant was 
removed, the cells were washed with 0.01 М phosphate 
buffered saline (PBS) рН 7.2, and fixed by 80% cold 
acetone for 20 min. The cells were washed again with PBS 
and blocked with 5% skim milk in PBS (PBS-M) for 1 h 
at 37°C with the subsequent addition of 100  µl/well of 
subtype specific mAb to НА of А(H1N1)pdm09 or A(H3N2) 
influenza viruses in a concentration of 5–10 µg/ml 
in PBS-M. After a 2 h incubation at 37°C, non-bound 
mAb were removed and a mouse secondary IgG antibody 
bound to horseradish peroxidase (Sigma, USA) in PBS-M 
was added (dilution 1/10,000). The plates were incubated 
for 1  h at 37°С, washed and the substrate - 0.1 mg/ml 
3,3’,5,5’- tetramethylbenzidine (TMB) with 0.02% Н2О2 
in acetate-citric buffer (pH 5.0) was added. The reaction 
was stopped by the addition of 2 N H2SO4. The optical 
density (OD) of the resulting mixture was measured at 
450  nm (ОD450) using spectrophotometer Anthos-2010 
(Austria). Samples with uninfected cells were used as a 
negative control. The results with ОD450 values ≥ 2ОD450 
of the negative control samples were considered positive. 
RESULTS AND DISCUSSION 
During the epidemic season of 2014, the influenza 
viruses of A(H1N1)pdm09 subtype were isolated from 
the clinical samples in chicken embryos (1–3 passages). 
Viruses of A(H3N2) subtype were isolated in MDCK 
cell line. The presence of the influenza virus in all the 
samples was proved by means of the hemagglutination 
assay with human erythrocytes and by PCR analysis. The 
hemagglutination titers of isolated viruses varied from 
1/4 to 1/64.
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Three mAbs: #1 and #2, effectively interacting with the 
A/Texas/50/2012 (H3N2) and A/Switzerland/9715293/2013 
(H3N2) influenza viruses and #4 specifically binding to 
A/California/07/2009 (H1N1)pdm09 influenza virus, were 
created. The preliminary screening of these antibodies 
by immunoblotting, ELISA and HAI assays revealed that 
every one of them is directed to the HA1 subunit of the 
corresponding virus and is strongly subtype-specific. In 
order to confirm virus reproduction in cell lines, the mAb #3 
interacting with NP protein of all influenza A viruses 
was used. Viruses A/California/07/2009 (H1N1), A/Texas/ 
50/2012 (H3N2) and A/Switzerland/9715293/2013 (H3N2) 
were used as positive controls. 
The results presented in Fig.1 demonstrate that 
all the analyzed viruses reacted with NP specific 
mAb #3 while only viruses A/St.  Petersburg/1/2014, 
A/St.  Petersburg/16/2014, and A/St.  Petersburg/46/2014 
reacted with mAb#4 and demonstrated the same level 
of activity as the control virus A/California/07/2009 of 
the H1N1 subtype. Virus A/Texas/50/2012 of the (H3N2) 
subtype did not show any reactivity with mAb #4. These 
results prove that the viruses A/St.  Petersburg/1/2014, 
A/St.  Petersburg/16/2014, and A/St.  Petersburg/46/2014 
belong to the A(H1N1) subtype.
On the other hand, the viruses A/Astrahan/23/2014, 
A/Astrahan/24/2014, A/Astrahan/25/2014, A/Astrahan/ 
26/2014, A/Chita/261/2014, A/Chita/258/2014, A/Chita/ 
257/2014, A/St.Petersburg/80/2014, and A/Moscow/ 
252/2014 (Fig.2) reacted with the mAbs #1 and #2 
and were similar in this respect to the control viruses 
Fig.1. Interaction of human influenza viruses with mAbs #3 and #4 in cell-ELISA. Viruses: 1 - A/St. Petersburg/1/2014, 2 - A/St. Petersburg/ 
16/2014, 3 - A/St. Petersburg/46/2014, 4 – A/California/07/2009, 5 - A/Texas/50/2009 (H3N2). The influenza virus A/California/07/2009 
(H1N1) was used as the positive control and A/Texas/50/2009 virus of H3N2 subtype as the negative control of the mAb #4. The universal 
mAB #3 specific to the NP protein of influenza A viruses was used as a control of virus replication. 
Fig.2. Interaction of human influenza viruses with the monoclonal antibodies #1, #2, and #3 in cell-ELISA. Influenza viruses: 
1 – A/Astrahan/23/2014, 2 - A/Astrahan/24/2014, 3 - A/Astrahan/25/2014, 4 - A/Astrahan/26/2014, 5 – A/Chita/261/2014, 6 – A/Chita/258/2014, 
7 – A/Chita/257/2014, 8 – A/St. Petersburg/80/2014, 9 – A/Moscow/252/2014, 10 – A/Texas/50/2012, 11 – A/Switzerland/9715293/2013. 
Influenza viruses A/Texas/50/2009 and A/Switzerland/9715293/2013 of H3N2 subtype were used as the positive control of the mAbs #1 and 
#2. The universal mAB #3 specific to the NP protein of influenza A viruses was used as a control of virus replication.
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A/Texas/50/2012 and A/Switzerland/9715293/2013 of 
A(H3N2) subtype indicating that all of them belong to the 
A(H3N2) subtype. Thereby, the subtype differentiation of 
modern influenza A viruses can be performed by using 
the cell-ELISA with specific mAbs interacting exclusively 
with the HAs of the A(H1N1) or A(H3N2) virus subtypes.
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